Skip to content

Randomized controlled trial comparing letrozole and mifepristone pretreatment in medical management of first trimester missed miscarriage

Randomized controlled trial comparing letrozole and mifepristone pretreatment in medical management of first trimester missed miscarriage

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041480
Enrollment
Unknown
Registered
2020-12-27
Start date
2020-12-28
Completion date
Unknown
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

missed miscarriage

Interventions

mifepristone group:mifepristone 200mg orally
Letrozol: letrozole 10mg once a day for 3 consecutive days

Sponsors

The University of Hong Kong - Shenzhen Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: All women 18 years of age or older who were diagnosed with unexplained first trimester missed miscarriage were approached for enrolment into the study. Missed miscarriage was diagnosed by the ultrasound finding. Diagnostic criteria for missed miscarriage is the patient had no significant vaginal bleeding and the cervix was still closed. Transvaginal ultrasound shows: pregnancy sac is equal or more than 25mm, no yolk sac, embryo length is equal or more than 7mm no fetal pole. Whose gestational age is between 5 and 12 completed weeks were included in the study. Included the date of the first day of the last menstrual period to calculate gestational age.

Exclusion criteria

Exclusion criteria: Women who had an incomplete or inevitable abortion (defined as the absence of a gestational sac, an open cervical ,or both). A previous attempt to terminate the pregnancy, abnormal uterine lesions such as fibroids or congenital malformations, pregnancy despite an intrauterine contraceptive device (a known cause of miscarriage), medical disorders such as cardiac or hemorrhagic disease. Women who had a contraindication to mifepristone or misoprostol, suspected hydatidiform mole, patients who is breastfeeding.

Design outcomes

Primary

MeasureTime frame
Complete abortion rate;

Secondary

MeasureTime frame
side effects;patient satisfaction;the rate of urgent surgical intervention;

Countries

China

Contacts

Public ContactDu Libei

The University of Hong Kong - Shenzhen Hospital

dulb@hku-szh.org+86 18307556920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026